Assessing the Neonatal Safety of Indomethacin Tocolysis
- 1 July 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 106 (1), 173-179
- https://doi.org/10.1097/01.aog.0000168622.56478.df
Abstract
To systematically review and summarize the medical literature regarding the effects of tocolysis with indomethacin on neonatal outcome. We supplemented a search of entries in electronic databases with references cited in original studies and review articles to identify studies pertaining to indomethacin tocolysis and neonatal outcome. We evaluated, abstracted data, and performed quantitative analyses in studies assessing the neonatal outcomes of patients undergoing tocolysis with indomethacin. Observational studies and randomized trials were included in this systematic review. Forty-six studies were identified, 28 of which met criteria for systematic review and meta-analysis. These 28 studies included 6,008 infants. Of these infants, 1,621 were exposed to indomethacin for tocolysis antenatally; 4,387 infants not exposed to indomethacin served as the comparison group. An estimate of pooled odds ratios with 95% confidence intervals was calculated for dichotomous outcomes using random- and fixed-effects models. Observational studies and randomized trials were analyzed separately. Pooled estimates from observational studies and randomized trials revealed no significant differences in the rates of intraventricular hemorrhage, patent ductus arteriosus, necrotizing enterocolitis, or neonatal mortality between infants exposed to indomethacin antenatally and those not exposed. Meta-analysis of randomized trials revealed increased risk of bronchopulmonary dysplasia. However, the meta-analysis included only 3 randomized clinical trials, one of which showed increased risk. An association of bronchopulmonary dysplasia and indomethacin use was not noted in our analysis of observational studies. Although our pooled results did not identify significantly increased risks of adverse effects, the limited statistical power of published randomized trials does not allow us to exclude the possibility that indomethacin tocolysis increases the risk of adverse neonatal outcomes.Keywords
This publication has 49 references indexed in Scilit:
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Recent indomethacin tocolysis is not associated with neonatal complications in preterm infantsAmerican Journal of Obstetrics and Gynecology, 1999
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- Antenatal Indomethacin‐Adverse Fetal Effects ConfirmedAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1998
- Neonatal Complications after the Administration of Indomethacin for Preterm LaborNew England Journal of Medicine, 1993
- Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safetyAmerican Journal of Obstetrics and Gynecology, 1993
- Placental transfer of indomethacin in the human pregnancyAmerican Journal of Obstetrics and Gynecology, 1990
- The Myometrium and Uterine Cervix in Normal and Preterm LaborNew England Journal of Medicine, 1984
- Further study of the inhibition of premature labor by indomethacin Part II double-blind studyjpme, 1984
- The inhibition of premature labor with indomethacinAmerican Journal of Obstetrics and Gynecology, 1980